Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients with Primary Immunodeficiency

“…Patients require immunoglobulin replacement therapy, which can be administered intravenously (IVIG) or subcutaneously (SCIG) [7][8][9][10][11][12][13][14]. Subcutaneous administration produces stable serum IgG levels and is associated with fewer systemic adverse events (AEs).…”

Common variable immunodeficiency –

“…CVID patients have a tendency to form granulomas, which conforms it to sarcoidosis [39]. Granulomas can occur in any organ, the most frequently in the respiratory tract, liver, and spleen, rarely in the kidney, brain, conjunctiva, and skin [35].…”

“…Such a sequence of events in a number of cohort studies is estimated at 17-76% [24][25][26][27][28][29][30][31][32][33]. Early diagnosis usually protects the patient against this complication, however, development of bronchiectasis occurs even in 30% of patients, despite optimal treatment [34,35].…”

“…Infections of the nervous system: meningitis, encephalities and brain abscesses may also be rare but life-threatening manifestation of CVID. They are usually caused by S. pneumoniae, H. influenzae, S. aureus [25,38], but also by viral infections, especially enteroviruses [35]. CVID patients have a tendency to form granulomas, which conforms it to sarcoidosis [39].…”

“…and Shigella spp. play a statistically significant role in the etiology [33,35,38,40]. Giardiasis may manifest as diarrhea (watery or steatorrhea), spasmodic abdominal pain, bloating, and impaired nutritional status.…”